Dr. Gregory Gutierrez is a senior associate in Goodwin’s Life Sciences group.
Greg advises companies and investors on patent matters for life sciences and chemical innovations. He leverages his background in organic chemistry to help clients develop and manage global patent portfolios for their therapeutic products across all stages of clinical development, as well as after regulatory approval. He also supports clients during IP due diligence for various types of transactions, including M&A, venture financings, strategic partnerships, and public offerings.
Experience
Greg partners with life sciences companies of different sizes to build robust and valuable portfolios for a variety of product candidates, including small molecules, antibody-drug conjugates, peptides, biomaterials, and oligonucleotides. This encompasses patent protection for both composition of matter and next-generation inventions arising during product development, including course of treatment, solid forms/polymorphs, and drug product formulations. Greg is experienced in optimizing the exclusivities of FDA-approved products in anticipation of generic competition, including through patent term extension and Orange Book patent strategy. With respect to licensed assets, Greg often advises clients of their rights and obligations under the intellectual property provisions of license agreements.
Greg was previously a science advisor and law clerk at Goodwin. Prior to joining Goodwin, Greg was a technology specialist at an intellectual property-focused law firm in the Boston area.
Representative Matters
Credentials
Education
JD2021
Suffolk University Law School
PhDOrganic Chemistry2016
Massachusetts Institute of Technology
BAChemistry2011
Cornell University
Admissions
Bars
- California
- Massachusetts
- U.S. Patent and Trademark Office (USPTO)
Publications
- Co-author, “Patents and intellectual property in drug discovery,” Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier, 2025.
- Co-author, “The Federal Circuit Raises the Section 112 Stakes for Chemical Structures in Seagen v. Daiichi,” Goodwin Alert, December 2025.
- Author, “PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims to be Unpatentable,” Life Sciences Perspectives, January 2024.